Real-World study tracks COPD patients on triple therapy

NCT ID NCT05862545

Completed Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study followed 250 adults with COPD who were starting a new triple-combination inhaler (budesonide/glycopyrronium/formoterol, or BGF) in routine Italian clinics. Researchers measured how patients felt about their health after 12 weeks and up to a year. The goal was to see real-world improvements in symptoms and quality of life, not to test a cure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic obstructive pulmonary disease lung disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC OBSTRUCTIVE PULMONARY DISEASE

Contacts and locations

Locations

Research Site

Acquaviva delle Fonti, Italy
Research Site

Alessandria, Italy
Research Site

Ancona, Italy
Research Site

Avellino, Italy
Research Site

Brescia, Italy
Research Site

Brindisi, Italy
Research Site

Busto Arsizio (Varese), Italy
Research Site

Catania, Italy
Research Site

Catanzaro, Italy
Research Site

Cittadella (Padova), Italy
Research Site

Florence, Italy
Research Site

Foggia, Italy
Research Site

Lecce, Italy
Research Site

Naples, Italy
Research Site

Passirana (Milano), Italy
Research Site

Pavia, Italy
Research Site

Roma, Italy
Research Site

Torino, Italy
Research Site

Treviso, Italy
Research Site

Verona, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.